Canadian Manufacturing

SK Capital completes acquisition of Apotex

by CM staff   

Manufacturing Operations acquisition Apotex pharmaceutical SK Capital

Allan Oberman appointed as CEO to build Apotex into a Canadian-based global health company.

TORONTO — Apotex Pharmaceutical Holdings Inc. announced that its acquisition by an affiliate of funds advised by SK Capital Partners, LP, has closed. The company also announces that pharmaceutical executive Allan Oberman has been appointed President and CEO and member of the Board of Apotex.

Oberman has four decades of experience in corporate leadership to Apotex, including 20 years in the pharmaceutical industry. Most recently, he served as CEO of Concordia International Corp. and CEO of Sagent Pharmaceuticals Inc. Prior to these positions, he served as President and CEO of Teva Canada (formerly Novopharm Limited), COO of Teva International Group, President of Teva EMIA and President and CEO of Teva Americas Generics.

“We welcome Allan to the Apotex team. His experience leading major Canadian and international pharmaceutical companies and delivering enhanced shareholder value will benefit Apotex as we grow into a Canadian-based global health company,” said Aaron Davenport, Chairman of the Board of Apotex and Managing Director at SK Capital. “SK Capital looks forward to working with Apotex as it moves into its next phase of growth, leveraging its iconic brand, broad product portfolio, international presence and skilled team.”



Stories continue below

Print this page

Related Stories